Cough Mixtures – an overview

Christel Hanson, BPharm, BScHons, MSc(Med) Pharmacy
Tshwane University of Technology

Correspondence to: email: HansonC@tut.ac.za

Keywords: cough mixture, antitussives, mucolytic, guaifenesin, codeine, acetylcysteine, cough

Abstract

Cough mixtures are frequently prescribed for cough associated with upper respiratory diseases. Many different cough mixture combinations are available making an informed, therapeutically sound choice challenging for the pharmacist. Supportive evidence on the efficacy of cough mixtures in the alleviation of symptoms of colds and flu is not yet convincing. This review article aims to provide the pharmacist with knowledge and skills to make an appropriate informed choice of drug, individualised for the right patient, at the right time.

Introduction

Acute cough is usually due to the common cold. It is the most common symptom for which patients seek medical care. In a South African study, 79% of the mothers in the study group took their children to the clinic for coughing.¹ Cough is an important defensive reflex that helps clear secretions, foreign particles and irritants from breathing passages and can be a symptom of upper or lower respiratory tract infection.² An acute cough following an upper respiratory tract infection is usually self-limiting, but can be difficult to control and can be associated with impaired quality of life.³ Cough can be designated as acute (< 3 weeks in duration), prolonged acute (3 to 8 weeks in duration) or chronic (> 8 weeks in duration).⁴ In the majority of patients, acute cough is caused by upper respiratory tract infections (URTI), acute bronchitis or tracheo-bronchitis due to bacterial or, more frequently, viral infections. Cough is treated symptomatically either through non-pharmacological or pharmacological interventions.

In South Africa cough mixtures may be a combination of many different active ingredients, and there are more than 40 different cough mixtures listed in the Monthly Index of Medical Specialties (MIMS).⁵

Pharmacological therapy

Cough mixtures may be a combination of different active ingredients. These active pharmaceutical ingredients can be classified in the following pharmacological classes: antitussives, antihistamines and mucocoactive agents (mucolytic, expectorants, mucokinetics). In Table I these classes are summarised into examples, reported action, common adverse effects and interactions.

Therapeutic application

Antitussives/cough suppressants

Central antitussive agents can be useful in patients with chronic bronchitis, but have little efficacy in patients with cough due to upper respiratory infections. Dextromethorphan appears to have little serious toxicity.⁶ The safe dosage range seems to be considerably higher for dextromethorphan than for codeine. Use of these drugs is most appropriate in specific therapy such as patients with inoperable lung cancer and in cases in which an unproductive cough interferes with sleep or causes exhaustion.¹¹ The underlying cause of the dry cough should first be established to exclude conditions such as asthma and congestive heart failure. Peripheral and central antitussive agents can be useful in patients with chronic bronchitis, but have little efficacy in patients with cough due to upper respiratory tract infection. The use of cough suppressants in children under six years of age should be avoided due to its safety profile.

Antihistamines

Antihistamines are added to many cough and cold remedies as both antitussives and to treat rhinorrhoea and nasal congestion. Although some antihistamines may have an antitussive action, their clinical efficacy has not been well documented. The anticholinergic (atropine-like) action of antihistamines frequently causes a drying sensation in the throat and nasal passages and may result in thickening of bronchial secretions.¹⁴

Demulcents

Demulcents consist of sugar, honey, lemon or glycerol and act by increasing saliva production and swallowing, thereby interfering
Table I: Pharmacological treatment options 6, 7, 8, 9,10,11

<table>
<thead>
<tr>
<th>Classification</th>
<th>Example</th>
<th>Reported action</th>
<th>Common adverse effects</th>
<th>Drug-drug interactions; Drug-disease interactions, contra-indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cough suppressants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antitussives (cough suppressants)</strong></td>
<td>Pholcodine, noscapine e.g. Nitepax®, Pholtex®</td>
<td>Centrally acting opioid derivative, directly suppressing medullary cough centre</td>
<td>Dizziness, sedation, nausea, constipation, headache</td>
<td>Caution: Contra-indicated in children &lt; 2 years Contra-indicated in pregnancy Risk of opioid dependence, potential abuse</td>
</tr>
<tr>
<td></td>
<td>Dextromethorphan e.g. Benylin dry cough®</td>
<td>Centrally active N-Methyl-D-aspartate (NMDA) receptor antagonist; directly suppresses medullary cough centre</td>
<td>Sedation, dizziness, nausea (rare), respiratory depression, confusion, excitation (in overdose)</td>
<td>Drug-drug interactions: Alcohol, CNS drugs’ sedative action may be enhanced Drug-disease interactions: Asthma, liver impairment, respiratory depression. Patient with history of opioid dependency Caution: Not recommended for children &lt; 6 years Pregnancy: relatively safe (Category C)</td>
</tr>
<tr>
<td></td>
<td>Codeine phosphate</td>
<td>Suppresses cough reflex by suppressing the cough centre in medulla</td>
<td>Sedation, constipation, nausea</td>
<td>Caution: Risk of opioid dependence, potential abuse</td>
</tr>
<tr>
<td><strong>Antihistamines</strong></td>
<td>Diphenhydramine, chlorpheniramine, diphenhydramine promethazine, triprolidine, diphenylpyraline e.g. Expectalin® (Diphenhydramine); Expigen® (ammonium chloride)</td>
<td>Reduces the cholinergic transmission of nerve impulses in the cough reflex Reduces frequency of coughing</td>
<td>Sedation, headache, dizziness, nervousness, restlessness, irritability, palpitations, dry mouth, urinary retention</td>
<td>Drug-disease interaction: Contra-indicated in patients with narrow-angle glaucoma and prostatic hypertrophy due to anticholinergic/antimuscarinic properties Drug-drug interaction: Potentiates effects of anxiolytics, hypnotics, analgesics, alcohol and other CNS depressants Potentiates anticholinergic effects with sympathomimetic drugs</td>
</tr>
<tr>
<td></td>
<td>Sucrose, honey alcohol</td>
<td>Coats the throat and soothes irritated mucous membranes</td>
<td></td>
<td>Drug-disease interactions: Preparations with added sugar should not be used in patients with diabetes mellitus due to its influence on glucose levels</td>
</tr>
<tr>
<td><strong>Demulcents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mucoactive agents</strong></td>
<td>Guaiifenesin, ammonium chloride, sodium citrate, glyceryl guaiacolate e.g. Benylin wet cough® (guaifenesin)</td>
<td>Stimulates secretions and reduces mucus viscosity. Reduces bronchial spumt surface tension</td>
<td>Drowsiness, dizziness, headache, rash</td>
<td>Drug-disease interactions: Use with caution in patients with gastro-intestinal ulcers</td>
</tr>
<tr>
<td></td>
<td>Carboxysteine e.g. Mucospect®</td>
<td>Regulates metabolism of mucus-producing cells</td>
<td>Nausea, vomiting, headache, diarrhoea</td>
<td>Drug-disease interactions: Caution in asthmatics, and history of peptic ulcers.</td>
</tr>
<tr>
<td><strong>Mucoregulators</strong></td>
<td>N-Acetylcysteine (NAC) e.g. Solmucol®</td>
<td>Depolymerises the mucin glycoprotein oligomers by hydrolysing the disulphide bonds in mucoproteins to reduce the viscosity of secretions</td>
<td>Nausea, vomiting, broncho-spasm, headache, fever, urticaria, skin rashes, abdominal pain and diarrhoea</td>
<td>Drug-disease interactions: Caution in asthmatics, and history of peptic ulcers</td>
</tr>
<tr>
<td></td>
<td>Bromhexine</td>
<td>Loosens and thins bronchial secretions by reducing surface tension and viscosity of mucus</td>
<td>Gastro-intestinal effects, allergic reactions, broncho-spasm, dizziness, headache</td>
<td>Drug-disease interactions: Caution in asthmatics, and history of peptic ulcers</td>
</tr>
<tr>
<td><strong>Mucolytics</strong></td>
<td>Terbutaline, theophylline e.g. Alcophyllin®, Nuelin®</td>
<td>Improves cough clearance by increasing expiratory flow, reduction in volume of mucus secretion</td>
<td>Headache, fine tremor, insomnia, dizziness, tachycardia</td>
<td>Drug-disease interactions: Use with caution in patients with cardiac arrhythmias, ischaemic heart disease, uncontrolled hypertension or hyperthyroidism</td>
</tr>
</tbody>
</table>
with the cough reflex, or by coating the peripheral sensory receptors that trigger the cough. Demulcents may help reduce coughing associated with a dry irritated throat. Some cough syrups contain up to 40% alcohol and should never be used.14

**Mucoactive agents**

The main purpose of mucoactive agents is to increase the ability to decrease mucus hypersecretion and/or increase the ability to expectorate sputum. In a review article by Balsamo, mucoactive drugs are classified according to their mechanism of action into expectorants (guaifenesin, hypertonic saline), mucoregulators (carbocysteine, anticholinergic agents, glucocorticosteroids, macrolide antibiotics), mucolytics (N-acetylcysteine) and mucokinetics (bronchodilators and surfactants).11 In this article, we will only focus on the agents used in combination.

**Expectorants**

Guaifenesin is the most common expectorant and the dose required to be effective is 100–200 mg per dose for adults.15 It has no mucolytic action but may reduce bronchial sputum surface tension. Guaifenesin can stimulate the cholinergic pathway and increase mucus secretion from the airway submucosal glands.10 Ammonium chloride, sodium citrate, glyceryl guaiacolate failed to show better efficacy than placebo in several randomised control trials (RCT).9

**Mucoregulators**

Carbocysteine has long been on the market and is frequently used as a single agent or in combination with other cough preparations. Carbocysteine may modulate airway inflammation by reducing the production of cytokines in rhinovirus infections. Additional evidence shows that carbocysteine inhibits the adherence of bacteria and viruses to ciliated epithelial cells in vitro.11

**Mucolytics**

Mucolytics decrease mucus viscosity. Evidence suggests that N-acetylcysteine (NAC) may also protect against free radical damage.11 A systemic review found N-acetylcysteine (NAC) may decrease cough after six to seven days of therapy in children older than two years.15

**Mucokinetics/bronchodilators**

Mucokinetics increase mucociliary clearance by acting on the cilia in airways. The β₂-adrenergic agonists, such as terbutaline, also enhance mucociliary function and may be of benefit in patients with cystic fibrosis.10 Bronchodilators work through their direct relaxation effect on airway smooth muscle cells. At present, three major classes of bronchodilators, β₂-adrenoceptor (AR) agonists, muscarinic receptor antagonists, and xanthines are available and can be used individually or in combination. Orciprenaline and terbutaline are moderately selective β₂ adrenergic receptor agonists and should be used with caution in patients with cardiac arrhythmia, diabetes and hyperthyroidism.15 Theophylline has a narrow therapeutic index; serum levels slightly outside the target ranges may lead to serious toxicity or lack of efficacy. Unpredictable and erratic elimination kinetics, especially in children and elderly patients increase the risk for toxic effects.12

**Cough suppressant/antitussive combinations**

Two other classes of cough preparations commonly added to cough suppressants are decongestants (α-adrenergic agonists on capillary blood vessels of nasal mucosa), and expectorants like ammonium chloride, sodium chloride, glyceryl guaiacolate and guaifenesin. These combinations’ therapeutic goal is probably to relieve symptoms of a blocked nose (congestion), dry cough, expectoration of phlegm and bronchoconstriction (wheeze). Products combining an expectorant and cough suppressant are illogical as they have opposing effects and should not be advocated.8

**Expectorant combinations**

Expectorant combinations include decongestants, bronchodilators and cough suppressants. Combinations of expectorant and cough suppressant are not advisable, as they have opposing actions on the mucus, the one suppressing the cough and the other assisting with coughing out of mucus.18 Combinations of decongestants, expectorants and bronchodilators could be of benefit for patients with blocked noses, wheeze and cough with mucus hypersecretion.

**Bronchodilator combinations**

Theophylline (xanthine), and orciprenaline (β₂-adrenoceptor (AR) agonists) as bronchodilators are frequently combined with mucolytics such as bromhexine. Oral bronchodilators should be administered at higher doses than the dose in the cough mixtures, to be effective for bronchospasm. At this dose, systemic side-effects such as tremor, insomnia and tachycardia are unavoidable. Combining muscarinic acetylcholine receptor antagonists and

---

**Table II: Cough mixture combinations available in South Africa**

<table>
<thead>
<tr>
<th>Combination</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihistamine + decongestants + cough suppressant</td>
<td>Bronchodilator + mucolytic</td>
</tr>
<tr>
<td>Antihistamine + expectorant + bronchodilator</td>
<td>Antihistamine + decongestant + expectorant + cough suppressant</td>
</tr>
<tr>
<td>Antihistamine + expectorant</td>
<td>Bronchodilator + expectorant</td>
</tr>
<tr>
<td>Bronchodilator + expectorant</td>
<td>Bronchodilator + mucolytic</td>
</tr>
</tbody>
</table>

**Table III: When to refer a patient with cough to the doctor**

- Presence of thick yellow sputum or green phlegm, indicating possible bacterial infection
- Fever > 38.6 °C
- Night-time coughing
- Weight-loss (unintentional)
- History or symptoms of underlying chronic disease
- Aspiration of foreign objects
- Drug-associated cough
- Coughing more than seven days
- Cough not responding to appropriate medication
- Infant or child who has a bark-like cough, stridor or hoarseness

---
β₂-adrenoceptor agonists is a pharmacologically reasonable choice as muscarinic antagonists reduce the bronchoconstrictor effects of acetylcholine and β₂-adrenoceptor enhance the bronchial smooth muscle relaxation effect, thus bronchodilation. Antimuscarinic agents can suppress mucus/fluid secretions resulting in changes in surface tension.¹⁷

**Choice of drug therapy**

When cough alone is a major problem, using a full dose of a single drug aimed at a specific component of the cough reflex is preferred.¹⁴

<table>
<thead>
<tr>
<th>Table IV</th>
<th>Component of cough reflex</th>
<th>Drug therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-productive cough.</td>
<td>Antitussive-dextromethorphan preferred to codeine.</td>
<td></td>
</tr>
<tr>
<td>Bronchoconstriction associated with cough.</td>
<td>Bronchodilators (inhaled) combined with expectorants.</td>
<td></td>
</tr>
<tr>
<td>Cough originating from pharyngeal region.</td>
<td>Demulcent syrups combined with cough suppressant (dextromethorphan).</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion**

Treatment with cough mixtures should be individualised for each patient and is indicated for short-term, symptomatic treatment of acute cough. Some cough mixtures are illogical and should be avoided. Assessing a patient’s symptoms and providing appropriate treatment recommendations is an important service pharmacists provide.

**References**